Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...
(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a ...
Amid a looming standoff with activist investor Starboard Value, Pfizer fought back against accusations of underperforming by delivering double digit revenue growth over the third quarter and notchi | ...
Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...
Pfizer has today reported higher-than-expected third quarter profit due to strong sales of Covid-19 treatment Paxlovid, an ...
Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...
“Desidustat was invented in India, and patients with sickle cell disease need therapies in addition to the currently available drug Hydroxyurea. So our vision is to ensure that India continues ...
Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback